Marksans Pharma Ltd (MARKSANS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524404 | NSE: MARKSANS | Pharmaceuticals & Drugs | Small Cap

Marksans Pharma Share Price

183.95 -3.95 -2.10%
as on 05-Dec'25 16:59

Marksans Pharma Ltd (MARKSANS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524404 | NSE: MARKSANS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Marksans Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Marksans Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
35.34
Market Cap:
8,515 Cr.
52-wk low:
162.1
52-wk high:
358.5

Is Marksans Pharma Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Marksans Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Marksans Pharma Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 22.5%3.4%4.9%12%11.4%23.5%19.9%14.3%14.8%18.8%-
Value Creation
Index
0.6-0.8-0.7-0.1-0.20.70.40.00.10.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3582162954244336006586558531,1741,251
Sales YoY Gr.--39.7%36.5%44%2.2%38.3%9.8%-0.5%30.2%37.6%-
Adj EPS 1.70.10.210.92.42.21.82.83.95.3
YoY Gr.--94%80%450%-6.1%160.2%-9.5%-16.4%54.1%36.5%-
BVPS (₹) 1010.210.511.512.414.716.924.52730.533
Adj Net
Profit
68.33.97.340.737.999.189.583.1128175241
Cash Flow from Ops. 64.8-13.615.619.81081075651.734.131-
Debt/CF from Ops. 0.6-5.44.33.9000.1000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 14.1%22.1%21.3%37.6%
Adj EPS 9.7%32.9%20.7%36.5%
BVPS13.2%19.8%21.8%13.2%
Share Price 5.9% 23.6% 44.4% -47.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
17.50.91.797.817.912.98.81113.416.8
Op. Profit
Mgn %
27.86.39.914.916.519.117.312.816.417.720.2
Net Profit
Mgn %
19.11.82.59.68.816.513.612.71514.919.3
Debt to
Equity
0.10.20.20.20000000
Working Cap
Days
206352278223227165187238253240161
Cash Conv.
Cycle
127260208160157105121146143133114

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Marksans Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 5.3 7.8
TTM Sales (₹ Cr.) 1,251 2,731
BVPS (₹.) 33 59.3
Reserves (₹ Cr.) 1,450 2,643
P/BV 5.70 3.17
PE 35.34 24.21
From the Market
52 Week Low / High (₹) 162.05 / 358.50
All Time Low / High (₹) 0.70 / 358.50
Market Cap (₹ Cr.) 8,515
Equity (₹ Cr.) 45.3
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Marksans Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Marksans Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Marksans Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3582162954244336006586558531,174
Operating Expenses 259202266361362486545582713970
Manufacturing Costs22191921182317407295
Material Costs178112169236245338378394479640
Employee Cost 264046464955605677102
Other Costs 333132575070909185133
Operating Profit 991429637111411473140204
Operating Profit Margin (%) 27.7%6.3%9.9%14.9%16.5%19.0%17.3%11.1%16.4%17.4%
Other Income 13187803142796270
Interest 6487754411
Depreciation 1515129121518172929
Exceptional Items 0000000000
Profit Before Tax 9212175653124135132172243
Tax 200412152631293855
Profit After Tax 711212443898104103134188
PAT Margin (%) 20.0%5.3%4.2%10.3%8.7%16.4%15.8%15.7%15.7%16.0%
Adjusted EPS (₹)1.80.30.31.10.92.42.52.33.04.2
Dividend Payout Ratio (%)7%18%16%5%11%10%10%22%20%19%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 4234194294715066006921,1111,2231,383
Share Capital 53414141414141454545
Reserves 3693783884304655596511,0661,1771,338
Minority Interest0000000000
Debt41736677005000
Long Term Debt0000000000
Short Term Debt41736677005000
Trade Payables31213437576474112160204
Others Liabilities 393331404897218146166209
Total Liabilities 5345465606256107619891,3691,5481,796

Fixed Assets

Gross Block184196202225249277301319414555
Accumulated Depreciation87102114122134148166175143172
Net Fixed Assets 979488103115129136144272383
CWIP 0000000400
Investments 231234236236236236237266293266
Inventories442942707594104131191205
Trade Receivables133155169178162169247305370550
Cash Equivalents 33123106224440312269
Others Assets 2531243619274378111123
Total Assets 5345465606256107619891,3691,5481,796

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 65-14162010810756523431
PBT 9212175653124135132172243
Adjustment 913201219-9-811-16-8
Changes in Working Capital -15-22-16-354612-39-60-83-158
Tax Paid -20-16-5-13-10-20-32-32-39-47
Cash Flow From Investing Activity -177-8-8-20-249-128-195-11417
Capex -22-12-6-23-24-21-23-35-155-120
Net Investments -164-3-2000-120-149-489
Others 970302915-104548
Cash Flow From Financing Activity -5221-101-82-1471210-26-30
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -3-4-8-7-7-5-3-400
Dividend Paid -7-6-2-2-2-4-11-10-23-27
Others -4231010-72-485224-4-3
Net Cash Flow -164-1-212102-167-10618

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)18.912.792.939.77.7717.816.1111.4111.4614.45
ROCE (%)22.453.444.9211.9911.3923.4619.9114.2714.8118.76
Asset Turnover Ratio0.670.40.530.720.70.880.760.590.590.7
PAT to CFO Conversion(x)0.92-1.171.330.452.841.090.540.50.250.16
Working Capital Days
Receivable Days132244200149143100114145144142
Inventory Days48624448615154626961
Payable Days7884595570656786103104

Marksans Pharma Ltd Stock News

Marksans Pharma Ltd FAQs

The current trading price of Marksans Pharma on 05-Dec-2025 16:59 is ₹183.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Marksans Pharma stood at ₹8,515.
The latest P/E ratio of Marksans Pharma as of 04-Dec-2025 is 35.34.
The latest P/B ratio of Marksans Pharma as of 04-Dec-2025 is 5.70.
The 52-week high of Marksans Pharma is ₹358.5 and the 52-week low is ₹162.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Marksans Pharma is ₹1,251 ( Cr.) .

About Marksans Pharma Ltd

Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.

The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

Marksans Pharma  acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.

Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.

In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited

Business area

Research and Development- The company’s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.

Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in Asia. The company’s manufacturing plants are located at Goa and UK.

APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.

CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.

Milestones

2009 - Marksans Pharma establlished itself as a global player
2008 - Acquired Bells, Sons & Co. (Druggists) Ltd.
          Acquired Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.
          Changed its name to "Marksans Pharma Ltd"
2001  - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×